Results come after positive results from a trial among people with idiopathic pulmomary disease.

Lupin introduces ipratropium bromide nasal solution, 0.03% & 0.06% in US markets: Our Bureau, Mumbai Friday, July 4, 2025, 17:30 Hrs [IST] Global pharma major Lupin Limited (Lupin ...

Lupin announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States. Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are ...

The Business Research Company The Business Research Company's Asperger Syndrome Market 2025: Strategic Insights for Business Growth, Expans ...

Ipratropium bromide nasal solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with ...

Lupin has announced the launch of Ipratropium Bromide Nasal Solution (nasal spray) in two strengths in the United States.

Lupin Ltd has introduced Ipratropium Bromide nasal spray in the US, available in 0.03% and 0.06% strengths. These sprays, ...

Mumbai: Global pharma major Lupin Limited has launched Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in ...

Germany’s Boehringer Ingelheim has selected a third drug candidate to move forward into IND-enabling studies under its ongoing collaboration with Oxford BioTherapeutics.

Canada's Foot-and-Mouth Disease vaccine bank is closer with new supply contracts, enhancing livestock protection and safeguarding trade.

Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford ...

Boehringer Ingelheim Pharma GmbH & Co KG has selected a third oncology drug candidate to advance into IND-enabling studies under its ongoing collaboration with Oxford Biotherapeutics Ltd.